Corporate
2021.05.25
Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection
(May 25th, 2021, Taipei) Lumosa Therapeutics is pleased to announce today the execution of an exclusive distribution agreement with PrJSC Pharmaceutical Firm Darnitsa (“Darnitsa”) for LT1001 in Ukraine. Darnitsa is one of the largest pharmaceutical companies in Ukraine. The company develops, manufactures, and markets generic, prescription, and over-the-counter products in several therapeutic areas including pain management. According to the agreement, Darnitsa is responsible for the registration, sales, and marketing of LT1001 in Ukraine, and Lumosa will supply LT1001 drug product. Lumosa is looking forward to working with Darnitsa to bring this unique product to the Ukrainian analgesic market, as well as gaining possible access to the Eastern European countries and Commonwealth of Independent States.
Corporate
2021.02.01
LT3001 Compound Patent Approved in Korea and Europe
Patents Approved in South Korea and European Countries for Lumosa's Novel Treatment for Acute Ischemic Stroke Encouraging Global Patent Position and Advancements in Clinical Studies
Corporate
2020.12.17
Naldebain Approved by Singapore HSA
Lumosa is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, from Singapore’s Health Science Agency (HSA). Being one of the regulatory reference countries, HSA's approval has significance in accelerating the marketing of LT1001 in the rest of ASEAN member states. Applications for drug approval were also submitted to the health authorities of other Southeast Asian countries such as Malaysia and Thailand. Applications to the rest of ASEAN countries will soon follow.
Corporate
2020.12.14
Lumosa to commence a multi-dose Phase 1 trial right after the single-dose Phase 2 to expand stroke treatment methodology
LT3001 is a novel treatment for acute ischemic stroke (AIS), currently under development by Lumosa Therapeutics (Lumosa). The company will proceed with a multi-dose and drug-drug-interaction Phase I trial right after the enrollment completion of the single-dose Phase II study for LT3001. The study will help Lumosa to obtain safety data and pharmacokinetic parameters as the administration frequency is increased, to establish foundations for the coming Phase II multiple-dose trial.
Corporate
2020.12.04
Enrollment Completed for 1st Phase 2 Trial for LT3001
Lumosa is pleased to announce that the company has completed the #enrollment of its first Phase 2 clinical trial for #LT3001, a new chemical entity for the treatment of acute ischemic stroke. The data is expected to come out in Q1 of 2021.
Corporate
2020.09.14
LT3001 Received IND Approval from China's NMPA
Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its China partner Shanghai Pharmaceutical Holding (SHP) has received the IND approval from China’s NMPA for the lead drug candidate, LT3001, a novel treatment for acute ischemic stroke. A phase 2 clinical study is currently on-going in the US and Taiwan. Once China studies are initiated, the clinical trials from Chinese sites will contribute additional data to accelerate LT3001 towards market approval.